Keywords included "SBRT," "immunotherapy," "cGAS-STING," "abscopal effect," and "tumor microenvironment." We specifically synthesized evidence comparing the immunobiological impacts of ablative versus immunogenic doses (e.g., the TREX1-cGAS-STING axis) and analyzed organ-specific immune tolerance mechanisms.<h4>Results</h4>Evidence suggests a "dose-dependent immunomodulatory window," where moderate hypofractionation (e.g., 8 Gy x 3) optimally induces type I interferons via the cGAS-STING pathway, whereas single high doses (>12-18 Gy) may dampen immunity through TREX1 induction. Here, STING1 is linked to neoplasm.